Stratipath, a forerunner in AI-based precision cancer diagnostics, is proud to announce that globally recognized breast oncologist, Professor Daniel F. Hayes, has joined the company’s Scientific Advisory Board. Professor Hayes will collaborate closely with the board, chaired by Professor Jonas Bergh, to further advance Stratipath’s innovative solutions in breast cancer precision diagnostics.
Stratipath’s flagship solution, Stratipath Breast, has been in clinical use for almost two years, providing groundbreaking AI-based prognostic risk profiling of breast cancer tumours. As the company enters a pivotal phase of expanding clinical adoption and ramping up validation and research for future solutions, Professor Hayes’ expertise will be instrumental in shaping the company’s path forward.
“Daniel Hayes is a global leader in breast oncology, with major experiences regarding prognostication and therapy predictions for breast cancer, and in integrating science into clinical care,” said Professor Jonas Bergh, Chair of Stratipath’s Scientific Advisory Board. “Having him join our board is a testament to Stratipath’s vision of revolutionising precision diagnostics through AI.”
“Professor Hayes brings unique insights into clinical guidelines and regulatory strategies, which are critical for the adoption of novel solutions like Stratipath Breast,” added Johan Hartman, Chief Medical Officer and Co-founder of Stratipath. “His contributions will be invaluable as we continue to solidify the scientific foundation of our work.”
Professor Hayes about joining the advisory board:
“Advances in artificial intelligence are transforming cancer care, and Stratipath is at the forefront of this revolution,” said Professor Daniel Hayes. “Their commitment to scientific excellence and innovation makes them a key player in shaping the future of personalized medicine. I look forward to contributing to their mission of improving outcomes for breast cancer patients worldwide.”
About Professor Daniel Hayes
Dr. Daniel F. Hayes is the Stuart B. Padnos Professor of Breast Cancer Research at the University of Michigan Rogel Cancer Center and a former president of the American Society of Clinical Oncology (ASCO). He is a globally recognized leader in breast cancer research and has significantly influenced diagnostic testing, biomarker development, and treatment guidelines.
Professor Hayes has held numerous leadership roles in ASCO since joining in 1986, including his presidency and serving on the Board of Directors including participation in several Expert Panels related to breast cancer, such as the ASCO-College of American Pathologists Estrogen Receptor/Progesterone Receptor and HER2 Testing Panels (Co-Chair). He has also contributed to the Breast Cancer Consensus Panel, Use of Tumour Biomarkers in Advanced Breast Cancer, and Early-Stage Breast Cancer Panels, among others. He has received ASCO’s Gianni Bonadonna Breast Cancer Award and the Allen Lichter Visionary Leadership Award.
Professor Hayes has chaired the Breast Cancer Intergroup of North America’s Correlative Sciences Committee and the Southwest Oncology Group’s Breast Cancer Translational Medicine Committee. He has been actively involved with the Union for International Cancer Control (UICC) TNM Expert Advisory Panel on Breast Tumours and the Early Breast Cancer Clinical Trials Collaborative Group Executive Committee.
Dr. Hayes also serves as a Komen Scholar for the Susan G. Komen for the Cure Scientific Advisory Council. With his deep expertise in breast cancer research and care, he is a key figure in advancing the field globally.
Professor Hayes earned his undergraduate and master’s degrees in biochemistry from Indiana University and his medical degree from Indiana University School of Medicine. He completed his internship and residency at Parkland Memorial Hospital/University of Texas Southwestern Medical School, followed by a medical oncology fellowship at Harvard Medical School’s Dana-Farber Cancer Institute.
